Overview

Investigation of Laser Assisted Drug Delivery of NanoDOX®

Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This is a self-controlled single-site study of 10 healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do two visits of approximately 4 hours over two weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
NanoSHIFT LLC
Treatments:
Doxycycline